Pfizer vaccine generates most antibodies, comparative study suggests

pharmafile | November 15, 2021 | News story | Sales and Marketing  

Pfizer Inc. and BioNTech’s COVID-19 vaccine yielded the strongest immune response in a comparative study of four vaccines. The study, conducted by Stanford University, the Onom Foundation, and the National Centre for Zoonotic Diseases in Ulaanbaatar, compared the Pfizer, AstraZeneca, Sinopharm and Sputnik V vaccines.

The study was published in the journal Cell Host and Microbe, in which the Pfizer vaccine was seen to produce the most antibodies against the coronavirus, while Sinopharm’s inoculation was seen to be potentially susceptible to breakthrough coronavirus infections.

Levels of protective antibodies against the part of the virus which Sars-CoV-2 uses to infect human cells varied widely across each of the four vaccine groups tested. The reasons for these differences in immune responses are currently the subject of intense research.

The study was conducted in July among 196 fully-immunised people in Mongolia, where all four shots were used. The results suggested that Sinopharm recipients, who made up around 89% of vaccinated adults in Mongolia at the time, as well as the smaller number of individuals given Sputnik V or AstraZeneca vaccines, could be susceptible to breakthrough infections.

Differences in the immune responses found between each vaccine type is likely due to factors including the amount of active ingredients in each dose, and the interval between receiving the first and second jabs. “Relatively low” antibody concentrations were stimulated by the Sinopharm and Sputnik V vaccines, with intermediate levels for the AstraZeneca vaccine, and the highest values for the Pfizer-BioNTech vaccine.

The authors of the published study shared: “Additional public health interventions, such as booster vaccine doses, potentially with the more potent vaccine types, may be needed to further the COVID-19 pandemic in Mongolia and worldwide.”

Ana Ovey

Related Content

No items found

Latest content